DR. STEPHEN ALAN SHERWIN, M.D.
Osteopathic Medicine in San Francisco, CA
License number
California G41963
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
995 Ward 84 BUILDING 80, San Francisco, CA 94110
Phone
(415) 476-4082
(415) 317-1230
(415) 317-1230
Personal information
See more information about STEPHEN ALAN SHERWIN at radaris.comName
Address
Phone
4005 Dixie Canyon Ave, Sherman Oaks, CA 91423
3508 Clay St, San Francisco, CA 94118
Professional information
Dr. Stephen A Sherwin - MD (Doctor of Medicine)
Hospitals:
995 Potrero Ave SUITE 80, San Francisco 94110
995 Potrero Ave SUITE 80, San Francisco 94110
995 Potrero Ave SUITE 80, San Francisco 94110
Education:
Medical Schools
Harvard Medical School
Graduated: 1974
Harvard Medical School
Graduated: 1974
Gene Manipulation And Expression Using Genomic Elements
US Patent:
5578461, Nov 26, 1996
Filed:
Aug 5, 1993
Appl. No.:
8/102567
Inventors:
Stephen Sherwin - San Francisco CA
Sue Klapholz - Stanford CA
Arthur Skoultchi - Larchmont NY
Sue Klapholz - Stanford CA
Arthur Skoultchi - Larchmont NY
Assignee:
Cell Genesys, Inc. - Foster City CA
International Classification:
C12N 1500, C12N 500, C12N 138, C07H 2104
US Classification:
435 691
Abstract:
Expression of mammalian target genes is achieved by employing chromosomal target DNA, either native primary cells or YACs in a yeast host, where the YACs include a fragment of a mammalian chromosome, the fragment comprising the target gene. Employing homologous recombination, an amplifiable gene is integrated into the mammalian fragment at a site to allow for amplification. In the same step, or one or more steps, as desired, the mammalian gene and/or the transcriptional system may be modified by in vivo mutagenesis. The resulting construct from homologous recombination may then be transformed into a mammalian expression host and integrated into the host genome, either randomly or by homologous recombination. The amplifiable gene may then be amplified by an appropriate agent providing for multiple copies of the target gene and the expression host grown to provide for high yields of the desired wild-type or modified protein.
Gene Manipulation And Expression Using Genomic Elements
US Patent:
6015708, Jan 18, 2000
Filed:
Jun 5, 1995
Appl. No.:
8/462947
Inventors:
Stephen Sherwin - San Francisco CA
Sue Klapholz - Stanford CA
Arthur Skoultchi - Larchmont NY
Sue Klapholz - Stanford CA
Arthur Skoultchi - Larchmont NY
Assignee:
Cell Genesys, Inc. - Foster City CA
International Classification:
C12N 119, C12N 510, C12N 1581, C12N 1585
US Classification:
435325
Abstract:
Expression of mammalian target genes is achieved by employing chromosomal target DNA, either native primary cells or YACs in a yeast host, where the YACs include a fragment of a mammalian chromosome, the fragment comprising the target gene. Employing homologous recombination, an amplifiable gene is integrated into the mammalian fragment at a site to allow for amplification. In the same step, or one or more steps, as desired, the mammalian gene and/or the transcriptional system may be modified by in vivo mutagenesis. The resulting construct from homologous recombination may then be transformed into a mammalian expression host and integrated into the host genome, either randomly or by homologous recombination. The amplifiable gene may then be amplified by an appropriate agent providing for multiple copies of the target gene and the expression host grown to provide for high yields of the desired wild-type or modified protein.
Method And Compositions For The Treatment And Prevention Of Septic Shock
US Patent:
5055447, Oct 8, 1991
Filed:
Jun 27, 1989
Appl. No.:
7/371484
Inventors:
Michael A. Palladino - Foster City CA
Stephen A. Sherwin - San Francisco CA
Stephen A. Sherwin - San Francisco CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 3702
US Classification:
514 12
Abstract:
Methods and compositions are provided for the treatment or prophylaxis of septic shock caused by bacteremic infection. Therapeutically and prophylactically effective doses of transforming growth factor-beta are administered to patients, either alone or in combination with another therapeutic or prophylactic agent for treating this pathologic condition. Preferably, the transforming growth factor-beta is human transforming growth factor-beta, and most preferably TGF-. beta. sub. 1, TGF-. beta. sub. 2, or TGF-. beta. sub. 3.
Method For The Treatment Of Chronic Myelogenous Leukemia
US Patent:
4851219, Jul 25, 1989
Filed:
Nov 18, 1986
Appl. No.:
6/932434
Inventors:
Stephen A. Sherwin - San Francisco CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 4502
US Classification:
424 855
Abstract:
Gamma interferon is employed in the treatment of chronic myelogenous leukemia. Patients treated in the benign stage exhibit partial and, in some cases, complete responses to gamma interferon. Successful results have also been obtained with some patients in the blast stage of the disease as well as patients who had been found to be refractory to treatment with alpha interferon.
Combined Cellular And Immunosuppressive Therapies
US Patent:
5670148, Sep 23, 1997
Filed:
Sep 28, 1994
Appl. No.:
8/314452
Inventors:
Stephen A. Sherwin - San Francisco CA
Robert B. Dubridge - Belmont CA
Robert B. Dubridge - Belmont CA
Assignee:
Cell Genesys, Inc. - Foster City CA
International Classification:
C12N 1500, A01N 6300, A61K 3512
US Classification:
424 9321
Abstract:
Novel regimens are provided for administering foreign genetically modified allogeneic cells to a host by combining the administration of the cells with a reduced regimen of an immunosuppressive agent. Particularly, cells having a reduced level of Class I MHC antigens may be employed in a variety of cellular therapy situations, where foreign cells are engrafted to treat diseased states.